ANTI-EGFR MOAB TREATMENT IN COLORECTAL CANCER: LIMITATIONS, CONTROVERSIES, AND CONTRADICTORIES
作者： Lei Cheng , Wei Ren , Li Xie , Ming Li , Jiang Liu
DOI: 10.1007/S00280-014-2489-6
关键词: Colorectal cancer 、 Monoclonal antibody 、 Oncology 、 Chemotherapy 、 Kras mutation 、 Cetuximab 、 Tumor microenvironment 、 Internal medicine 、 Medicine 、 Panitumumab 、 Guideline
摘要: Anti-epidermal growth-factor receptor (EGFR) monoclonal antibody (MoAb) treatment for chemotherapy refractory or metastatic colorectal cancer has obtained great achievement. However, not every patient responds to such molecular-targeted agent well. Biomarkers associated with anti-EGFR resistance are limited KRAS mutation up now. It was recently reported that cross-talking molecular effectors interacted EGFR-related pathway were also negative predictor treatment. the data, controversial results, and contradictories between in vitro clinical studies restrict application of these new biomarkers. Although current theory tumor microenvironment supported multi-target treatment, results from less than expected. Moreover, WHO RECIST guideline response assessment MoAb queried by recent AIO KRK-0306 trial. This review focuses on controversies, contradictories, limitations, order uncover unmet needs status cancer.
springer.com
sci-hub.se 参考文章(91)
Jennifer E Hardingham, Amanda Townsend, Timothy J Price, Omar Mohyieldin, Shalini Sree Kumar, Matthew Borg, KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model. Gastrointestinal cancer research : GCR. ,vol. 7, pp. 23- 26 ,(2014)
Chen Mao, Ya‐Fang Huang, Zu‐Yao Yang, Da‐Yong Zheng, Jin‐Zhang Chen, Jin‐Ling Tang, None, KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. Cancer. ,vol. 119, pp. 714- 721 ,(2013) , 10.1002/CNCR.27804
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Juergen Lerchenmueller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Joerg Hielscher, Michael Scholz, Sebastian Mueller, Britta Schaefer, Dominik Paul Modest, Andreas Jung, Sebastian Stintzing, Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). Journal of Clinical Oncology. ,vol. 31, ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.LBA3506
Zexing Wang, Jing Xu, Weiwei Nie, Guichun Huang, Jinhai Tang, Xiaoxiang Guan, Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis European Journal of Clinical Pharmacology. ,vol. 70, pp. 225- 231 ,(2014) , 10.1007/S00228-013-1598-1
Dominik P. Modest, Ruediger P. Laubender, Sebastian Stintzing, Clemens Giessen, Christoph Schulz, Michael Haas, Ulrich Mansmann, Volker Heinemann, Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. Acta Oncologica. ,vol. 52, pp. 956- 962 ,(2013) , 10.3109/0284186X.2012.752580
Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Dongsheng Tu, Salvatore Siena, Simona Lamba, Sabrina Arena, Milo Frattini, Hubert Piessevaux, Eric Van Cutsem, Chris J. O’Callaghan, Shirin Khambata-Ford, John R. Zalcberg, John Simes, Christos S. Karapetis, Alberto Bardelli, Sabine Tejpar, Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab JAMA. ,vol. 304, pp. 1812- 1820 ,(2010) , 10.1001/JAMA.2010.1535
Zhen-Hua Wang, Qin-Yan Gao, Jing-Yuan Fang, Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies Cancer Chemotherapy and Pharmacology. ,vol. 69, pp. 1647- 1655 ,(2012) , 10.1007/S00280-012-1886-Y
Won Ki Kang, Jeeyun Lee, Yong Sang Hong, Jung Yong Hong, Se Won Han, Tae Won Kim, Hye Jin Kang, Tae You Kim, Kyu-pyo Kim, Suk Hyung Kim, In-Gu Do, Kyoung-Mee Kim, Insuk Sohn, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Yong Beom Cho, Woo Yong Lee, Seong Hyeon Yun, Hee Cheol Kim, Young Suk Park, Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab Investigational New Drugs. ,vol. 32, pp. 535- 541 ,(2014) , 10.1007/S10637-014-0065-X
Nicola Personeni, Steffen Fieuws, Hubert Piessevaux, Gert De Hertogh, Jef De Schutter, Bart Biesmans, Wendy De Roock, An Capoen, Maria Debiec-Rychter, Jean-Luc Van Laethem, Marc Peeters, Yves Humblet, Eric Van Cutsem, Sabine Tejpar, Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab : A fluorescent in situ hybridization study Clinical Cancer Research. ,vol. 14, pp. 5869- 5876 ,(2008) , 10.1158/1078-0432.CCR-08-0449
Andrew S. Allison, Margaret A. McIntyre, Colin McArdle, Fouad K. Habib, The insulin-like growth factor type 1 receptor and colorectal neoplasia: insights into invasion Human Pathology. ,vol. 38, pp. 1590- 1602 ,(2007) , 10.1016/J.HUMPATH.2007.03.013